Sanford T. Colb & Co. hosted a reception for 1000 guests at the INTA conference in Barcelona at the gardens of the Fairmont Hotel.
Sanford T. Colb and eight additional members of the firm attended the conference. View
Acting on behalf of a client in the pharmaceutical field, the firm has received a ruling in its client's favor from the Commissioner of Patents that Dexlansoprazole is a different substance than racemic Lansoprazole, such that a pharmaceutical preparation comprising Dexlansoprazole may serve as the basis for a Patent Term Extension despite the prior registration of a preparation comprising racemic Lansoprazole.
David Colb spoke on the subject of Patent Term Extensions at the AIPLA 2017 Mid-Winter Institute in Florida.
Sanford T. Colb & Co. congratulates its client, Valtech Cardio, Ltd., on entering into an agreement to be acquired by Edwards Lifesciences Corporation in a $1 billion share repurchase program which includes a purchase price of Valtech of $340 million in stock and cash at closing. (Source: http://www.edwards.com/ns20161128)
The Firm was successful in oppositions to Israel Patent Applications 177724 and 205606. The Deputy Commissioner accepted the oppositions and ordered that the applicant pay NIS 350,000 in costs and attorney's fees.